Zurcher Kantonalbank Zurich Cantonalbank Decreases Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Zurcher Kantonalbank Zurich Cantonalbank trimmed its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 24.6% during the 4th quarter, Holdings Channel.com reports. The fund owned 6,978 shares of the company’s stock after selling 2,277 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Day One Biopharmaceuticals were worth $102,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Arizona State Retirement System lifted its holdings in Day One Biopharmaceuticals by 8.2% in the 4th quarter. Arizona State Retirement System now owns 13,373 shares of the company’s stock worth $195,000 after buying an additional 1,010 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Day One Biopharmaceuticals by 352.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock worth $147,000 after purchasing an additional 7,841 shares during the period. Legato Capital Management LLC boosted its stake in shares of Day One Biopharmaceuticals by 14.3% during the 4th quarter. Legato Capital Management LLC now owns 41,918 shares of the company’s stock valued at $612,000 after purchasing an additional 5,242 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Day One Biopharmaceuticals by 74.9% during the fourth quarter. SG Americas Securities LLC now owns 64,692 shares of the company’s stock valued at $945,000 after buying an additional 27,712 shares during the period. Finally, Exchange Traded Concepts LLC raised its stake in Day One Biopharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after buying an additional 2,554 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of Day One Biopharmaceuticals stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the sale, the insider now owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Samuel C. Blackman sold 2,258 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the sale, the insider now owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Charles N. York II sold 2,666 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $40,656.50. Following the transaction, the chief financial officer now owns 277,754 shares in the company, valued at approximately $4,235,748.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 195,247 shares of company stock valued at $3,376,817. 8.40% of the stock is owned by corporate insiders.

Day One Biopharmaceuticals Price Performance

Shares of Day One Biopharmaceuticals stock opened at $16.38 on Friday. Day One Biopharmaceuticals, Inc. has a 1 year low of $9.67 and a 1 year high of $18.07. The firm’s 50-day moving average is $15.45 and its 200 day moving average is $14.20. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -6.88 and a beta of -1.44.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, equities analysts expect that Day One Biopharmaceuticals, Inc. will post -2.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. HC Wainwright cut their price objective on Day One Biopharmaceuticals from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday. Needham & Company LLC restated a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday. Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday. The Goldman Sachs Group dropped their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Monday, April 22nd. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.